Key Highlights

● Danaher rose with no confirmed company-specific news, part of a broad life-science tools rally.

● Charles River Laboratories led the group, hitting a 52-week high and finishing as the S&P 500's second-best performer.

● Medical-device makers Abbott, Stryker and Intuitive Surgical also climbed.

Danaher rose on Monday, Oct. 5, moving in step with a rally across life-science tools stocks even as most of the health care sector slipped.

No headline, but a strong group

Danaher (NYSE:DHR) rose on Monday, according to market data, ending among the gainers in the S&P 500.

The most visible driver was the group. Life-science tools stocks advanced together, led by Charles River Laboratories (NYSE:CRL), which climbed sharply to a 52-week high of $303.33 and finished as the second-best performer in the S&P 500. Thermo Fisher Scientific (NYSE:TMO) also climbed, and Illumina (NASDAQ:ILMN) jumped.

What Danaher does

Danaher is a science and technology conglomerate focused on life sciences, diagnostics and biotechnology. Its businesses Supply equipment and materials used to discover, develop and manufacture drugs, including the tools behind biologic medicines, as well as diagnostic tests used in hospitals and labs.

That puts Danaher at the centre of spending by pharmaceutical and biotech companies. When investors grow more upbeat on that spending, the tools names tend to move together, and Monday looked like one of those days.

A split health care sector

The tools rally ran against the grain of the wider health care sector, which was the weakest in the S&P 500 at midday and finished with a modest decline.

The big drugmakers bore the brunt. Merck (NYSE:MRK) was the worst performer in the Dow. Bristol-Myers Squibb (NYSE:BMY) slid after a Leerink Partners downgrade, and Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) both fell.

Medical-device makers fared better. Abbott Laboratories (NYSE:ABT), Stryker (NYSE:SYK) and Intuitive Surgical (NASDAQ:ISRG) all climbed. And vaccines drew buyers after Vaxcyte (NASDAQ:PCVX) reported positive Phase 3 data for its VAX-31 pneumococcal vaccine, while Moderna (NASDAQ:MRNA) rallied ahead of its entry into the Nasdaq-100.

Records on the Nasdaq, yields climb

The broader market finished higher. The Nasdaq Composite rose 286.45 points to a record close of 27,477.31, and the Nasdaq-100 set a record at 31,076.44. The S&P 500 gained 51.23 points to 7,773.95, just shy of its summer record, and the Dow Jones Industrial Average added 90.94 points to 51,267.90. Advancing S&P 500 stocks outnumbered decliners by 1.7 to 1, and materials was the best-performing sector.

That came despite pressure from bond markets. The 10-year Treasury Yield rose to its highest close since 2002. The ISM services survey showed prices paid at their highest since July 2022, while Friday's jobs report showed only 29,000 positions added in September. The weak jobs data cut the odds of another Fed rate hike in October to roughly one in four or less.

JPMorgan chief US economist Michael Feroli said: "It would now take a very strong CPI to make the October meeting live."

Oil eased, with Brent settling at $100.32 a barrel and US crude near $89.43, as a G7 plan to release emergency reserves calmed supply worries.

What to watch

For Danaher, the next big moment is its quarterly Earnings report, where investors will look for updates on Demand from biotech and pharmaceutical customers and on its diagnostics business. Reports from tools peers will also shape sentiment toward the group.

For the broader market, the Fed releases minutes of its September meeting on Wednesday, Oct. 7, at 2 p.m. ET. PepsiCo reports Thursday and Delta Air Lines Friday. Bank earnings begin on Oct. 13, and the Fed's next policy meeting is set for Oct. 27–28.